|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
488.20 EUR |
+2.76% | -9.05% | -18.63% | |
April 10, 2025 at 06:09 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Argenx Announces FDA Approval Of Vyvgart Hytrulo Prefilled Syringe For Self-Injection In Generalized Myasthenia Gravis And Chronic Inflammatory Demyelinating Polyneuropathy |
Apr. 10 |
RE |
|
US FDA approves syringe version of Argenx’s immune disorder drug |
Apr. 10 |
RE |
|
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading |
Apr. 09 |
MT |
|
Global pharma shares plunge as Trump doubles down on tariff threat |
Apr. 09 |
RE |
|
Argenx SE Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP |
Apr. 08 |
CI |
|
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading |
Mar. 27 |
MT |
|
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading |
Mar. 26 |
MT |
|
Immunovant’s muscle drug data underwhelms, shares gain on new drug promise |
Mar. 19 |
RE |
|
Bernstein Upgrades argenx to Outperform, Boosts PT |
Mar. 17 |
MT |
|
European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading |
Mar. 13 |
MT |
|
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week |
Mar. 07 |
MT |
|
Argenx Highlights FcRn Leadership with Long-Term Data and Transformational Patient Outcomes At the American Academy of Neurology 2025 Annual Meeting |
Mar. 07 |
CI |
|
Argenx Publishes Long-Term Data At The American Academy Of Neurology 2025 Annual Meeting |
Mar. 07 |
RE |
|
Argenx’s Q4 Sales Backed by Vyvgart’s Growth, Oppenheimer Says |
Feb. 28 |
MT |
|
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading |
Feb. 27 |
MT |
|
Argenx SE, Q4 2024 Earnings Call, Feb 27, 2025 |
Feb. 27 |
|
|
Argenx Q4 Swings to Earnings, Operating Income Increases |
Feb. 27 |
MT |
|
Immunology Company argenx Swings to Profit in FY24; Net Sales Climb |
Feb. 27 |
MT |
|
Argenx: $737 Million In Q4 Global Product Net Sales |
Feb. 27 |
RE |
|
Argenx SE Reports Earnings Results for the Full Year Ended December 31, 2024 |
Feb. 27 |
CI |
|
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading |
Feb. 20 |
MT |
|
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week |
Feb. 14 |
MT |
|
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading |
Feb. 11 |
MT |
|
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading |
Jan. 29 |
MT |
|
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading |
Jan. 15 |
MT |
ARGX: Dynamic Chart
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
More about the company
Buy
Last Close Price
488.20EUR
Average target price
702.29EUR
Spread / Average Target
+43.85%
Consensus
Quarterly revenue – Rate of surprise
}
